SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

被引:0
作者
Leiming Xia
Fan Yang
Xiao Wu
Suzhi Li
Chen Kan
Hong Zheng
Siying Wang
机构
[1] Basic College of Medicine,Department of Hematology
[2] Anhui Medical University,Department of Hematology
[3] The Third affiliated hospital of Anhui Medical University,Laboratory Center for Medical Science Education
[4] The fourth affiliated hospital of Anhui Medical University,undefined
[5] Anhui Medical University,undefined
来源
Cancer Cell International | / 21卷
关键词
SHP2; T790M mutation; Lung adenocarcinoma; CXCL8 feedback loop; Stemness; Osimertinib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 649 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2019)Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review JAMA 322 764-774
[3]  
Soerjomataram I(2016)Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis MOL CANCER 15 67-285
[4]  
Siegel RL(2011)International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 244-550
[5]  
Torre LA(2014)EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice Nature 511 543-1828
[6]  
Jemal A(2013)Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing Br J Cancer 109 1821-1567
[7]  
Arbour KC(2019)Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning PLOS ONE 14 e224379-2140
[8]  
Riely GJ(2018)Comprehensive characterization of oncogenic drivers in asian lung adenocarcinoma NAT MED 24 1559-e459
[9]  
Marshall EA(2016)Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer J Thorac Oncol 11 2129-50
[10]  
Ng KW(2015)Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC Lancet Oncol 16 e447-47